Oral Minoxidil for Late Alopecia in Cancer Survivors

    Alyce Mei-Shiuan Kuo, Rachel Reingold, Kwami F. Ketosugbo, Alexander Pan, Lukas Kraehenbuehl, Stephen W. Dusza, Devika Gajria, Diana Lake, Jacqueline Bromberg, Tiffany A. Traina, Monica Fornier, Ayca Gucalp, B D'Alessandro, Veronica Rotemberg, Megan Dauscher, Jerry Shapiro, Shari Goldfarb, Alina Markova, Mario E. Lacouture
    TLDR Oral minoxidil effectively improves hair regrowth in cancer survivors with late alopecia.
    The study investigated the impact of oral minoxidil on late alopecia in 216 female cancer survivors, mainly with breast cancer, who suffered hair loss from chemotherapy and/or endocrine therapy. After a median of 105 days on oral minoxidil, 74% of participants showed hair regrowth improvement, as confirmed by standardized photography. In a subset of 42 patients, quantitative trichoscopic assessments indicated significant increases in hair shaft density in both frontal and occipital regions. The treatment was well tolerated, with no discontinuations due to adverse events, indicating that oral minoxidil may effectively enhance hair density in cancer survivors with late alopecia.
    Discuss this study in the Community →

    Research cited in this study

    25 / 25 results

    Related Community Posts Join

    6 / 1000+ results

      community Goodbye tressless. I’ve decided to give in to my hairloss.

      in Update  597 upvotes 3 years ago
      Kitchen_Plastic_2847 had been fighting hair loss since 2019-2020 and was initially successful in regrowing his hair with finasteride. However, after contracting Covid three times back to back at the start of 2021, he started to lose his hair again. He found a new dermatologist who prescribed him oral minoxidil along with finasteride, but eventually decided it wasn't worth spending all the money to try and save his hair.

      community Chat is this real? Compound called clascoterone

      in Research/Science  584 upvotes 3 months ago
      Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

    Related Research

    10 / 10 results